| Species |
Human |
| Protein Construction |
TROP-2/TACSTD2 (His27-Thr274)
Accession # P09758 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Immobilized TROP-2/TACSTD2 hFc Chimera, Human (Cat.No.: Z03840) at 1 μg/ml (100μl/Well) on the plate can bind Biotinylated Anti-TROP-2 Antibody. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
54.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Trop-2 (Tumor-associated calcium signal transducer 2) is also known as epithelial glycoprotein-1 antigen (EGP-1). It is encoded by the TACSTD2 gene. The mutations of Trop-2 gene cause an autosomal recessive disorder. Trop-2 causes cancer cell growth, proliferation, invasion, migration, and survival of cancer cells |
| Synonyms |
EGP1; EGP-1; TROP2; GA733-1; gp50; T16; TACSTD2; TROP-2; M1S1; TACD2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
